Literature DB >> 25873827

Conservative management of chylothorax after coronary artery bypass grafting.

Gokalp Altun, Zerrin Pulathan, Dilek Kutanis, Dogus Hemsinli, Engin Erturk, Ali Civelek.   

Abstract

Chylothorax is a rare sequela to cardiac surgery, associated with high rates of morbidity and mortality. There are various medical and surgical options for its management. We describe 2 cases of chylothorax that developed after coronary artery bypass grafting and were managed successfully with medical therapy alone. Conservative treatment such as we describe aims to reduce chyle flow, to drain the pleural cavity in an effective manner, and to prevent chronic sequelae. Optimal conservative treatment, consisting of nothing by mouth and the administration of a pleurodetic agent, should be started immediately upon diagnosis. In most cases, it reduces the need for reoperation and long-term hospitalization. Prospective randomized controlled trials are nonetheless needed to confirm these assumptions.

Entities:  

Keywords:  Chylothorax/diagnosis/therapy; coronary artery bypass/adverse effects; pleurodesis; postoperative complications; somatostatin; thoracic duct/injuries

Mesh:

Year:  2015        PMID: 25873827      PMCID: PMC4382882          DOI: 10.14503/THIJ-13-3532

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  21 in total

Review 1.  Chylothorax complicating thoracic surgery: conservative or early surgical management?

Authors:  Panagiotis Misthos; Meletios A Kanakis; Achilleas G Lioulias
Journal:  Updates Surg       Date:  2012-01-13

2.  Octreotide for treating chylothorax after cardiac surgery.

Authors:  Dalokay Kilic; Ekber Sahin; Oner Gulcan; Bulent Bolat; Riza Turkoz; Ahmet Hatipoglu
Journal:  Tex Heart Inst J       Date:  2005

3.  Successful octreotide treatment of chylothorax following coronary artery bypass grafting procedure. A case report and review of the literature.

Authors:  Nikolaos Barbetakis; Theocharis Xenikakis; Andreas Efstathiou; Ioannis Fessatidis
Journal:  Hellenic J Cardiol       Date:  2006 Mar-Apr

4.  Traumatic chylothorax following blunt thoracic trauma: two conservatively treated cases.

Authors:  Efstratios Apostolakis; Karolina Akinosoglou; Efstratios Koletsis; Dimitrios Dougenis
Journal:  J Card Surg       Date:  2009 Mar-Apr       Impact factor: 1.620

5.  Chylomediastinum following mitral valve replacement.

Authors:  I Tasoglu; G Lafci; S Sahin; D E Sert; M M Ulas
Journal:  Thorac Cardiovasc Surg       Date:  2011-06-20       Impact factor: 1.827

6.  Management of refractory chylothorax after pediatric cardiovascular surgery.

Authors:  S Matsuo; G Takahashi; A Konishi; S Sai
Journal:  Pediatr Cardiol       Date:  2012-12-11       Impact factor: 1.655

7.  Chylothorax in children after congenital heart surgery.

Authors:  Shu-yan Chan; Wendy Lau; Wilfred H S Wong; Lik-cheung Cheng; Adolphus K T Chau; Yiu-fai Cheung
Journal:  Ann Thorac Surg       Date:  2006-11       Impact factor: 4.330

8.  Postoperative chylothorax after cardiothoracic surgery in children.

Authors:  Emily H Chan; Jennifer L Russell; William G Williams; Glen S Van Arsdell; John G Coles; Brian W McCrindle
Journal:  Ann Thorac Surg       Date:  2005-11       Impact factor: 4.330

9.  The successful use of octreotide in the treatment of traumatic chylothorax.

Authors:  Annabel J Sharkey; Jagan N Rao
Journal:  Tex Heart Inst J       Date:  2012

Review 10.  Chylothorax after coronary artery bypass surgery.

Authors:  Olatunde Falode; Ian Hunt; Christopher P Young
Journal:  J R Soc Med       Date:  2005-07       Impact factor: 18.000

View more
  2 in total

1.  Surgical technique and chylothorax following coronary artery bypass grafting.

Authors:  Achilleas Lazopoulos; Dimitrios Paliouras; Nikolaos Barbetakis
Journal:  Ann Card Anaesth       Date:  2018 Oct-Dec

2.  Yellow nail syndrome with chylothorax after coronary artery bypass grafting.

Authors:  Sarah Waliany; Julia Chandler; David Hovsepian; Jack Boyd; Natalie Lui
Journal:  J Cardiothorac Surg       Date:  2018-09-11       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.